6.63
Starling Oncology, Inc. Common Stock stock is traded at $6.63, with a volume of 1.85M.
It is up +7.28% in the last 24 hours and up +7.46% over the past month.
See More
Previous Close:
$6.18
Open:
$6.18
24h Volume:
1.85M
Relative Volume:
1.68
Market Cap:
$675.70M
Revenue:
Net Income/Loss:
P/E Ratio:
-
EPS:
-
Net Cash Flow:
1W Performance:
+5.24%
1M Performance:
+7.46%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Starling Oncology, Inc. Common Stock Stock (STLN) Company Profile
Name
Starling Oncology, Inc. Common Stock
Sector
Industry
Phone
-
Address
-
Compare STLN vs HCA, THC, EHC, DVA, FMS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
STLN
Starling Oncology, Inc. Common Stock
|
6.63 | 675.70M | 0 | 0 | 0 | 0.00 |
|
HCA
Hca Healthcare Inc
|
456.96 | 98.93B | 76.39B | 7.81B | 7.93B | 29.08 |
|
THC
Tenet Healthcare Corp
|
268.08 | 21.59B | 21.46B | 2.65B | 3.35B | 19.23 |
|
EHC
Encompass Health Corp
|
124.55 | 12.29B | 6.07B | 793.80M | 464.40M | 5.9914 |
|
DVA
Davita Inc
|
181.34 | 11.57B | 13.84B | 1.10B | 1.49B | 10.42 |
|
FMS
Fresenius Medical Care Ag Adr
|
21.20 | 11.28B | 22.44B | 1.35B | 2.03B | 1.9002 |
Starling Oncology, Inc. Common Stock Stock (STLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-06-26 | Initiated | Lake Street | Buy |
| Nov-25-25 | Initiated | Needham | Buy |
| Jul-23-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-16-25 | Initiated | B. Riley Securities | Buy |
| May-15-25 | Initiated | BTIG Research | Buy |
| Feb-26-24 | Resumed | Jefferies | Buy |
| Sep-14-22 | Initiated | Guggenheim | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
View All
Starling Oncology, Inc. Common Stock Stock (STLN) Latest News
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation - The Manila Times
UMH PROPERTIES, INC. DECLARES COMMON AND PREFERRED DIVIDENDS - The Manila Times
ARMOUR Residential REIT, Inc. Confirms October 2026 Common Share and Q4 2026 Series C Preferred Share Dividends - The Manila Times
Compass Diversified Declares Third Quarter 2026 Distributions on Series A, B and C Preferred Shares - The Manila Times
Antelope Enterprise Holdings Limited Announces $100 Million 'At-the-Market' Equity Offering Program - The Manila Times
Nutriband Marks Five Years on NasdaqCEO Letter to Shareholders - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation - www.marketscreener.com
Starling Oncology, Inc.(NasdaqCM:STLN) added to S&P Health Care Services Select Industry Index - marketscreener.com
Income Statement - Intellectia AI
3 Growth Companies With High Insider Ownership Growing Earnings Up To 132% - simplywall.st
Vice Chairman Bradford Hively Sold A Bunch Of Shares In Starling Oncology - Simply Wall Street
Starling Oncology (STLN) director sells 298K shares under 10b5-1 plan - Stock Titan
Nearly $2M in Starling Oncology (STLN) stock planned for director sale - Stock Titan
Starling Oncology (TOI) holder pairs 12K-share buy with call option sale - Stock Titan
Starling Oncology launches platform for treatment authorization - Investing.com
Starling Oncology Company Profile & Introduction - Moomoo
Starling Oncology And 2 Other Growth Stocks Insiders Are Backing - simplywall.st
US$9.00That's What Analysts Think Starling Oncology, Inc. (NASDAQ:STLN) Is Worth After These Results - simplywall.st
Starling Oncology (STLN) Stock Rerates On Cash Gains As Margin Risks Linger - simplywall.st
Oncology Institute (STLN) Stock Price, News & Analysis $STLN - marketbeat.com
Starling Oncology, Inc.STLNStock Price Today - Zacks Investment Research
The Oncology Institute, Inc. (STLN) Stock Price, News, Quote & History - Yahoo! Finance Canada
What date does Starling Oncology, Inc.'s (STLN) report EarningsEarnings Calendar & Announcement - zacks.com
Earnings call transcript: Starling Oncology Q2 2026 revenue tops forecast, stock jumps - Investing.com
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance - GlobeNewswire
Diluted net income available to common stockholders of Starling Oncology, Inc. – NASDAQ:STLN - TradingView
The Oncology Institute Rebrands as Starling Oncology - Yahoo Finance
The Oncology Institute, Inc. will Change its Ticker to STLN from TOI - marketscreener.com
The Oncology Institute Reports Fourth Quarter and Full Year 2025 Financial Results and Guidance for 2026 - GlobeNewswire
The Oncology Institute (TOI) Stock Price, News & Analysis - Stock Titan
The Oncology Institute Warrant (TOIIW) Stock Price, News & Analysis - Stock Titan
The Oncology Institute announces $110 million strategic - GlobeNewswire
P3 Health Partners Inc. (PIIIW) Stock Price, News, Quote & History - Yahoo! Finance Canada
DFP Healthcare Acquisitions Corp. Announces Proposed Business Combination With The Oncology Institute - Business Wire
Starling Oncology, Inc. Common Stock Stock (STLN) Financials Data
There is no financial data for Starling Oncology, Inc. Common Stock (STLN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Starling Oncology, Inc. Common Stock Stock (STLN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BRADFORD HIVELY | Director |
Aug 21 '26 |
Proposed Sale |
6.54 |
298,853 |
1,954,499 |
0 |
| Chernett Jorey | 10% Owner |
Aug 14 '26 |
Buy |
6.54 |
12,000 |
78,480 |
10,660,858 |
| Chernett Jorey | 10% Owner |
Jul 21 '26 |
Buy |
5.27 |
18,000 |
94,860 |
10,648,858 |
| Podnos Yale | Chief Medical Officer |
Jul 14 '26 |
Option Exercise |
1.90 |
23,452 |
44,567 |
277,501 |
| Podnos Yale | Chief Medical Officer |
Jul 14 '26 |
Sale |
6.41 |
23,452 |
150,340 |
259,527 |
| YALE PODNOS | Officer |
Jul 14 '26 |
Proposed Sale |
6.25 |
23,452 |
146,575 |
0 |
| Chernett Jorey | 10% Owner |
Jul 10 '26 |
Buy |
5.85 |
15,000 |
87,750 |
10,630,858 |
| Chernett Jorey | 10% Owner |
Jun 23 '26 |
Buy |
5.02 |
18,000 |
90,360 |
10,615,858 |
| Podnos Yale | Chief Medical Officer |
Jun 08 '26 |
Sale |
5.38 |
23,451 |
126,094 |
259,527 |
| YALE PODNOS | Officer |
Jun 08 '26 |
Proposed Sale |
4.87 |
23,451 |
114,206 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):